V184

Themis Bioscience GmbH · Phase 2 active Biologic

At a glance

Generic name	V184
Also known as	MV-CHIK, MV-CHIK vaccine, MV-CHIK/DP (drug product)
Sponsor	Themis Bioscience GmbH
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V184 CI brief — competitive landscape report
V184 updates RSS · CI watch RSS
Themis Bioscience GmbH portfolio CI